A statistically significant survival difference was found between the PSG+ and PSG− groups in uterine cancer with a log-rank p of 0.0138 and borderline significance in kidney cancer with a log-rank p of 0.0746 (Supplemental Fig. 3). This evidence concerns the gene PSG5 and kidney cancer.